

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
28 October 2004 (28.10.2004)



PCT

(10) International Publication Number  
**WO 2004/091520 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K** [US/US]; 1111 Franklin Street, Oakland, CA 94607-5200 (US).
- (21) International Application Number: **PCT/US2004/011333**
- (22) International Filing Date: **12 April 2004 (12.04.2004)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data: **60/462,654** **11 April 2003 (11.04.2003)** **US**
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application: **60/462,654 (CIP)** **US** **11 April 2003 (11.04.2003)**
- (71) Applicant (for all designated States except US): **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA**
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **WITZTUM, Joseph, L. [—/US]; 6912 Ofria Court, San Diego, CA 92120 (US). CHANG, Mi-Kyung [—/US]; 10860 Caminito Arcada, San Diego, CA 92131 (US). SILVERMAN, Gregg, J. [—/US]; 571 Hidden Ridge Court, Encinitas, CA 92024 (US). SHAW, Peter, X. [—/US]; 10860 Caminito Arcada, San Diego, CA 92131 (US). BINDER, Christoph [—/US]; 390 Stratford Court, Apt. 2, Del Mar, CA 92014 (US).**
- (74) Agent: **REED, Michael; Fish & Richardson P.C., 12390 El Camino Real, San Diego, CA 92130 (US).**
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,**

[Continued on next page]

(54) Title: **METHODS AND COMPOSITIONS FOR TREATING ATHEROSCLEROSIS**



(57) **Abstract:** During the progression of atherosclerosis, autoantibodies are induced to epitopes of oxidized low-density lipoprotein (OxLDL), and active immunization of hypercholesterolemic mice with OxLDL ameliorates atherogenesis. The present studies have identified anti-OxLDL autoantibodies that share complete genetic and structural identity with antibodies produced by anti-phosphorylcholine B-cell clone, T15.